A prospective study was conducted of the rapid FASTPlaque-Response test for determination of rifampicin resistance in Mycobacterium tuberculosis with and without the addition of an antimicrobial supplement containing nystatin, oxacillin and aztreonam (NOA) to control specimen-related contamination. A total of 631 smear-positive sputum specimens was tested. The age of specimens ranged from 0 to 21 days. The NOA antimicrobial was effective at controlling contamination, with 4.1 % of specimens contaminated when the NOA antimicrobial supplement was used compared with 13.9 % contamination without NOA. Overall levels of interpretability of the test with NOA were 87.8 % with specimens of ≤3 days and 79.0 % for all specimens. This compared with 70.1 and 73.8 % readable results, respectively, from conventional culture-based drug susceptibility testing (DST). Sensitivity, specificity and overall accuracy of the FASTPlaque-Response test for rifampicin resistance were 98.1, 96.3 and 96.6 %, respectively, for all specimens with NOA, and 93.2, 96.3 and 95.9 % without NOA, when compared with resolved conventional DST results. Inclusion of the NOA supplement reduced contamination, increased the number of interpretable results and did not adversely affect the performance of the FASTPlaque-Response test. Thus, the use of NOA improves the robustness of the test, facilitating its wider implementation.
AlbertH.,
HeydenrychA.,
MoleR.,
TrollipA. P.,
BlumbergL.2001; Evaluation of FASTPlaque TB -RIF , a rapid, manual test for the determination of rifampicin resistance from M. tuberculosis cultures. Int J Tuberc Lung Dis 5:906–911
AlbertH.,
HeydenrychA.,
BrookesR.,
MoleR. J.,
HarleyB.,
SubotskyE.,
HenryR.,
AzevedoV.2002; Performance of a rapid phage-based test, FASTPlaque TB, to diagnose pulmonary tuberculosis from sputum specimens in South Africa. Int J Tuberc Lung Dis 6:529–537
CrucianiM.,
ScarparoC.,
MalenaM.,
BoscoO.,
SerpelloniG.,
MengoliC.2004; Meta-analysis of BACTEC MGIT 960 and BACTEC 460TB, with and without solid media, for detection of Mycobacteria
. J Clin Microbiol 42:2321–2325[CrossRef]
EnarsonD. A.,
RiederH. L.,
ArnadottirT.,
TrebucqA.2000Management of Tuberculosis. A Guide for Low Income Countries Paris: International Union Against Tuberculosis and Lung Disease;
FischlM. A.,
DaikosG. L.,
UttamchandraniR. B.,
PobleteR. B.,
MorenoJ. N.,
ReyesR. R.,
BootaA. M.,
ThompsonL. M.,
ClearyT. J.other authors1992; Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple drug resistant bacilli. Ann Intern Med 117:184–190[CrossRef]
GuerraH.,
HenostrozaG.,
RojasG.other authors2005; Evaluation of a phage amplification assay for detection of MDR-TB in smear-positive patients in Lima, Peru. Int J Tuberc Lung Dis 9 (Suppl. 1):S196
HeifetsL. B.,
CangelosiG. A.1999; Drug susceptibility testing in Mycobacterium tuberculosis : a neglected problem at the turn of the century. Int J Tuberc Lung Dis 3:564–581
JacobsW. R.,
BarlettaR. G.,
UdaniR.,
ChanJ.,
KalkutG.,
SosneG.,
KieserT.,
SarkisG. J.,
HatfullG. F.,
BloomB. R.1993; Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science 260:819–822[CrossRef]
MorganM.,
KalantriS.,
FloresL.,
PaiM.2005; A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis : a systematic review and meta-analysis. BMC Infect Dis 5:62[CrossRef]
MuzaffarR.,
BatoolS.,
AzizF.,
NaqviA.,
RizviA.2002; Evaluation of the FASTPlaque TB assay for direct detection of Mycobacterium tuberculosis in sputum specimens. Int J Tuberc Lung Dis 6:635–640
PaiM.,
KalantriS.,
DhedaK.2006; New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn 6:423–432[CrossRef]
SeamanT.,
TrollipA.,
MoleR.,
AlbertH.2003; The use of a novel phage-based technology as a practical tool for the diagnosis of tuberculosis in Africa. Afr J Biotechnol 2:40–45[CrossRef]
SuarezP. G.,
FloydK.,
PortocarreroJ.,
AlarconE.,
RapitiE.,
RamosG.,
BonillaC.,
SabogalI.,
ArandaI.other authors2002; Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359:1980–1989[CrossRef]
VictorT. C.,
JordaanA. M.,
van RieA.,
van der SpuyG. D.,
RichardsonM.,
van HeldenP. D.,
WarrenR.1999; Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridisation strategy. Tuber Lung Dis 79:343–348[CrossRef]
WilsonS. M.1997; Method to detect bacteria
. PCT patent WO97/022713
WilsonS. M.,
Al-SuwaidiZ.,
McNerneyR.,
PorterJ.,
DrobniewskiF.1997; Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis
. Nat Med 3:465–468[CrossRef]